Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016

  • ID: 3775395
  • Drug Pipelines
  • 69 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Alligator Bioscience AB
  • Apexigen, Inc.
  • Apogenix GmbH
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016

Summary

‘Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Review, H1 2016’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Alligator Bioscience AB
  • Apexigen, Inc.
  • Apogenix GmbH
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Overview

Therapeutics Development

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Stage of Development

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Therapy Area

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Indication

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Companies

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Companies Involved in Therapeutics Development

Alligator Bioscience AB

Apexigen, Inc.

Apogenix GmbH

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celldex Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

Kyowa Hakko Kirin Co., Ltd.

Novartis AG

Seattle Genetics, Inc.

Zyrnat Biotherapeutics SL

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Drug Profiles

2C-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADC-1013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APG-1233 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-005M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-655064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bleselumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FFP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGYY-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize CD40 for Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7876 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEA-CD40 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZY-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Dormant Projects

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) - Featured News & Press Releases

Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting

Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences

Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn’s Disease with anti-CD40 Monoclonal Antibody

Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe

Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting

Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M

May 28, 2015: Alligator Bioscience Phase 1 Trial Benefits from Cobra Biologics maxXpress Platform

Apr 27, 2015: First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial

Apr 07, 2015: Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial

Feb 17, 2015: Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors

Dec 05, 2012: Boehringer Ingelheim And Apexigen Sign Manufacturing Agreement For Process Development And Early Stage Clinical Supply

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Alligator Bioscience AB, H1 2016

Pipeline by Apexigen, Inc., H1 2016

Pipeline by Apogenix GmbH, H1 2016

Pipeline by Boehringer Ingelheim GmbH, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Celldex Therapeutics, Inc., H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Seattle Genetics, Inc., H1 2016

Pipeline by Zyrnat Biotherapeutics SL, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Alligator Bioscience AB
  • Apexigen, Inc.
  • Apogenix GmbH
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE
Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis.

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 5 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Our latest report Tumor Necrosis Factor Receptor Superfamily Member 5 – Pipeline Review, H1 2016, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Alligator Bioscience AB
Apexigen, Inc.
Apogenix GmbH
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celldex Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Novartis AG
Seattle Genetics, Inc.
Zyrnat Biotherapeutics SL
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll